title: [Potentially treatable subacute forms of infection due to the HTLV-1].
abstract: BACKGROUND
  Tropical spastic paraparesis due to HTLV-I virus is diagnosed at very advanced stages, when there is spinal atrophy present and so only symptomatic treatment can be given. Early diagnosis of HTLV-I infection in unusual syndromes and the use of corticosteroids may help to slow the development of the disease.
  
  
  METHODS
  We describe two Brazilian patients who developed symptoms due to HTLV-I present for less than one year: subacute myelopathy with a sensory level and an ataxic pyramidal syndrome associated with axonal neuropathy, which partly improved after treatment with corticosteroids.
  
  
  RESULTS
  A 50 year old woman presented with progressive paraparesis following pain, cramps, feeling that her legs had 'gone to sleep' and sphincter dysfunction over the previous eleven months. Spinal MR showed a diffuse spinal hypersignal at D2. The 60 year old man had developed an ataxic syndrome and axonal polyneuropathy over the previous ten months. In both patients the anti-HTLV antibodies in blood and CSF were positive on ELISA as later confirmed by Western-blot. Thorough biochemical study ruled out other infectious etiologies. Both patients were treated with corticosteroids (i.v. methylprednisolone and oral prednisone respectively) and their symptoms improved, particularly the joint pains, ataxia and the 'gone to sleep' sensation of the legs.
  
  
  CONCLUSIONS
  The ataxic syndrome and myelopathy due to HTLV-I, when these have been diagnosed early, may benefit from corticosteroid treatment and progression of the disorder be prevented. The myelitic phase of HTLV-I infection is associated with diffuse myelopathy, which was unusually seen in our first patient on spinal MR.
authors.affiliation: Servicio de Neurología, Red SARAH de Hospitales del Aparato Locomotor, Hospital Sarah-Brasilia DF, Brasilia, Brasil. javier@bsb.sarah.br
authors.forename: F J
authors.initials: FJ
authors.lastname: Carod-Artal
authors.forename: M
authors.initials: M
authors.lastname: Melo
authors.forename: R
authors.initials: R
authors.lastname: Alves
authors.forename: C
authors.initials: C
authors.lastname: Brenner
authors.forename: M C
authors.initials: MC
authors.lastname: del Negro
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001259:Ataxia / Q000175:diagnosis / Q000209:etiology; D001284:Atrophy / Q000473:pathology; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015490:HTLV-I Infections / Q000503:physiopathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D015493:Paraparesis, Tropical Spastic / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D011241:Prednisone / Q000627:therapeutic use; D012720:Severity of Illness Index; D013116:Spinal Cord / Q000473:pathology; D019467:Subacute Care
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone; D008775:Methylprednisolone